Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma (DOI:10.1016/j.exphem.2008.10.014);Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma

Experimental Hematology

Volumn 37, Issue 2, 2009, Pages 234-244

  O'Neal, Julie ^a   Gao, Feng ^a   Hassan, Anjum ^b   Monahan, Ryan ^a   Barrios, Samantha ^a   Lee, Ian ^c   Chng, Wee J ^c,d   Vij, Ravi ^a   Tomasson, Michael H ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; NEUROBEACHIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE MARROW TUMOR; CHROMOSOME 13Q; CHROMOSOME DELETION 13; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; GENE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NERVE CELL; PRIORITY JOURNAL; RB1 GENE; SKIN BIOPSY; TUMOR SUPPRESSOR GENE;

EID: 58149195202     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.02.009     Document Type: Erratum

References (48)

1. Zandecki M., Lai J.L., and Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94 (1996) 217-227
2. Chiecchio L., Protheroe R.K., Ibrahim A.H., et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20 (2006) 1610-1617
3. Shaughnessy Jr. J., Tian E., Sawyer J., et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 120 (2003) 44-52
4. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
5. Aalto Y., Nordling S., Kivioja A.H., Karaharju E., Elomaa I., and Knuutila S. Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma. Genes Chromosomes Cancer 25 (1999) 104-107
6. Avet-Loiseau H., Andree-Ashley L.E., Moore II D., et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 19 (1997) 124-133
7. Fonseca R., Oken M.M., Harrington D., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15 (2001) 981-986
8. Konigsberg R., Ackermann J., Kaufmann H., et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 14 (2000) 1975-1979
9. Zojer N., Konigsberg R., Ackermann J., et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95 (2000) 1925-1930
10. Nomdedeu J.F., Lasa A., Ubeda J., et al. Interstitial deletions at the long arm of chromosome 13 may be as common as monosomies in multiple myeloma. A genotypic study. Haematologica 87 (2002) 828-835
11. Shaughnessy J., Tian E., Sawyer J., et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96 (2000) 1505-1511
12. Carrasco D.R., Tonon G., Huang Y., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9 (2006) 313-325
13. Agnelli L., Bicciato S., Fabris S., et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 92 (2007) 56-65
14. Walker B.A., Leone P.E., Jenner M.W., et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108 (2006) 1733-1743
15. Sebat J., Lakshmi B., Troge J., et al. Large-scale copy number polymorphism in the human genome. Science 305 (2004) 525-528
16. Redon R., Ishikawa S., Fitch K.R., et al. Global variation in copy number in the human genome. Nature 444 (2006) 444-454
17. Kaelin Jr. W.G., Krek W., Sellers W.R., et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70 (1992) 351-364
18. Helin K., Lees J.A., Vidal M., Dyson N., Harlow E., and Fattaey A. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70 (1992) 337-350
19. Hiebert S.W. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol Cell Biol 13 (1993) 3384-3391
20. Venkatraman E.S., and Olshen A.B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23 (2007) 657-663
21. Workman C., Jensen L.J., Jarmer H., et al. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 3 (2002) 1-16
22. Western Electric Company. Statistical Quality Control Handbook. Indianapolis, Indiana; Western Electric Company: 46226, 1956.
23. SAS Institute, Inc. SAS Language (version 8). Gary, NC; SAS Institute Inc.: 1999.
24. Link D.C., Kunter G., Kasai Y., et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood 110 (2007) 1648-1655
25. Trudel S., Hua Z., Wei E., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 (2005) 2941-2948
26. Bolstad B.M., Irizarry R.A., Astrand M., et al. A Comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics 19 (2003) 185-193
27. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. PNAS U S A 98 (2001) 5116-5121
28. Li C., and Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 98 (2001) 31-36
29. Xiang Z., Kreisel F., Cain J., Colson A., and Tomasson M.H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 27 (2007) 267-282
30. Harrison C.J., Mazzullo H., Ross F.M., et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Hematol 117 (2002) 427-435
31. Avet-Loiseau H., Stephanie D.A., Saunier S., et al. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 111 (2000) 1116-1117
32. Goodrich D.W., Wang N.P., Qian Y.W., Lee E.Y., and Lee W.H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67 (1991) 293-302
33. Elnenaei M.O., Hamoudi R.A., Swansbury J., et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 36 (2003) 99-106
34. Valverde J.R., Alonso J., Palacios I., and Pestana A. RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet 6 (2005) 53
35. Juge-Morineau N., Mellerin M.P., Francois S., et al. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 91 (1995) 664-667
36. Ely S., Di Liberto M., Niesvizky R., et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 65 (2005) 11345-11353
37. Su Y., Balice-Gordon R.J., Hess D.M., et al. Neurobeachin is essential for neuromuscular synaptic transmission. J Neurosci 24 (2004) 3627-3636
38. Dyomin V.G., Chaganti S.R., Dyomina K., et al. BCL8 is a novel, evolutionarily conserved human gene family encoding proteins with presumptive protein kinase A anchoring function. Genomics 80 (2002) 158-165
39. Wang X., Herberg F.W., Laue M., et al. Neurobeachin: a protein kinase A-anchoring, beige/Chediak-Higashi protein homolog implicated in neuronal membrane traffic. J Neurosci 20 (2000) 8551-8565
40. Gutierrez N.C., Castellanos M.V., Martin M.L., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21 (2007) 143-150
41. Shaughnessy J., Jacoboson J., Sawyer J., et al. Continuous absence of metaphase defined cytogenetic abnormalitiies, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 101 (2003) 3849-3856
42. Lopez B., Vidal F., Martin L., et al. MCB. Gene control in germinal differentiation: RNF6, a transcription regulatory protein in the mouse sertoli cell. MCB 22 (2002) 3488-3496
43. Lee S., Jeong J., Majewski T., et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. PNAS U S A 104 (2007) 13732-13737
44. Jogl G., Shen Y., Gebauer D., et al. Crystal structure of the BEACH domain reveals an unusual fold and extensive association with a novel PH domain. EMBO J 21 (2002) 4785-4795
45. Savelyeva L., Sagulenko E., Schmitt J.G., and Schwab M. The neurobeachin gene spans the common fragile site FRA13A. Hum Genet 118 (2006) 551-558
46. Zhan F., Barlogie B., Arzoumanian V., et al. A gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109 (2007) 1692-1700
47. Levine A.J., Momand J., and Finlay C.A. The P53 tumour suppressor gene. Nature 351 (1991) 453-456
48. Wang J.W., Gamsby J.J., Highfill S.L., et al. Deregulated expression of LRBA facilitates cancer cell growth. Oncogene 23 (2004) 4089-4097